Assertio Logo.jpg
Assertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 Million
05. Dezember 2022 07:30 ET | Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Logo.jpg
Assertio Reports Third Quarter 2022 Financial Results
08. November 2022 16:01 ET | Assertio Holdings, Inc.
Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36%Increases Guidance for Net Product Sales and Adjusted EBITDADebt Refinancing Extends Maturity, Reduces Cost and...
Assertio Logo.jpg
Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
27. Oktober 2022 16:05 ET | Assertio Holdings, Inc.
LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Logo.jpg
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
27. Oktober 2022 09:00 ET | Assertio Holdings, Inc.
Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) --...
Assertio Logo.jpg
Assertio to Participate in October 2022 Investor Conferences
12. Oktober 2022 07:30 ET | Assertio Holdings, Inc.
LAKE FOREST, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Logo.jpg
Assertio to Participate in the 2022 Lake Street BIG6 Conference
07. September 2022 09:00 ET | Assertio Holdings, Inc.
LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Logo.jpg
Assertio Announces Closing of $70 Million Convertible Senior Notes Offering
25. August 2022 10:24 ET | Assertio Holdings, Inc.
LAKE FOREST, Ill., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Logo.jpg
Assertio Prices $60 Million Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024
22. August 2022 22:06 ET | Assertio Holdings, Inc.
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Logo.jpg
Assertio Announces Proposed Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024
22. August 2022 16:01 ET | Assertio Holdings, Inc.
LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Logo.jpg
Assertio Reports Second Quarter 2022 Financial Results
08. August 2022 07:00 ET | Assertio Holdings, Inc.
Net Product Sales Increase 40% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases to $22.9 million Raises Full Year Revenue and Non-GAAP Adjusted EBITDA Guidance LAKE FOREST, Ill., Aug. 08, 2022 ...